



## **Last day of trading in paid subscription units (Sw.BTU) and first day of trading for TO2 2020/2022**

**Last day of trading in BTU in Alzinova AB (publ) ("Alzinova" or the "Company") will be Wednesday November 18, 2020 and stop day will be Friday November 20, 2020. First day of trading in warrants of series TO2 2020/2022 is expected to be Tuesday November 24, 2020.**

Through the rights issue, which ended on October 14, 2020, the Company issued units consisting of shares and warrants of series TO2 2020/2022, raising approximately SEK 50m before deduction of issue related costs. Upon full exercise of the warrants of series TO2 2020/2022, the Company will receive an additional SEK 25-42m (depending on the final exercise price). The redemption period runs between January 24 - February 7, 2022.

The rights issue has now been registered with the Swedish Companies Registration Office (Sw. *Bolagsverket*) and last day of trading in Alzinova's BTU will be November 18, 2020. Stop day will be November 20, 2020. Shares and warrants of series TO2 2020/2022 are estimated to be delivered on the shareholders' account November 24, 2020.

First day of trading in warrants of series TO2 2020/2022 is expected to be November 24, 2020.

### **Advisers**

Redeye AB acted as financial adviser, Fredersen Advokatbyrå AB as legal adviser and Hagberg Aneborn Fondkommission AB as the issuing agent in the Rights Issue.

### **For more information, please contact:**

Kristina Torfgård, CEO Alzinova

Tel: +46 70 846 79 75

e-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

### **About Alzinova**

*Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer's disease targeting neurotoxic amyloid- $\beta$  oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid- $\beta$  oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the A $\beta$ CC peptide™ technology and the ambition is to expand the pipeline further. The Company's Certified Advisor on Nasdaq First North Growth Market is Corpura [info@corpura.se](mailto:info@corpura.se) +46 768-532 822. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com).*